08 Sep 2022 Governance

Statement from Leukaemia UK on the death of Her Majesty Queen Elizabeth II

On behalf of the Leukaemia UK team, Chair of Trustees, Chris Corbin OBE, has made the following statement:

“We are extremely saddened to hear the news of the death of Her Majesty Queen Elizabeth II.

Together with the nation and people around the world, we remember a true leader who gave her life to duty. The Queen’s dedication, diligence and integrity were an inspiration to all and we are thankful for an inspiring monarch, who gave her life in service of her country and the Commonwealth.

The Queen’s support for the charity sector has enabled charities in the UK to thrive during her reign and will have a lasting impact for those whom the charities support. 

We share our condolences with the entire Royal Family and especially the Queen’s children and grandchildren. Our thoughts are with them at this very difficult time.” 

Related posts

Leukaemia UK is the new name for the ‘Elimination of Leukaemia Fund’

9 November 2017

Leukaemia UK is the new name for the ‘Elimination of Leukaemia Fund’

We are a leading charity making a difference to families affected by leukaemia, lymphoma, myeloma and other blood cancers.

Leukaemia: Investigating stem cells to prevent cancer

11 January 2019

Leukaemia: Investigating stem cells to prevent cancer

Dr Alice Giustacchini, University College London and John Goldman Fellow

Can the unique differences between stem cells tell us how well CML treatment will work?

22 May 2023

Can the unique differences between stem cells tell us how well CML treatment will work?

What if we could predict how chronic myeloid leukaemia (CML) patients will respond to treatment? Could the unique signatures of CML stem cells hold the key to personalising treatment for…

£200 grants for people affected by leukaemia once again available

4 April 2023

£200 grants for people affected by leukaemia once again available

Leukaemia UK and Leukaemia Care have this month relaunched the ‘Cost of Living Fund’, providing financial grants of £200 to patients with leukaemia, myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPNs),…